# Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

> **NCT03731234** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 75 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03731234
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-02
- **Primary completion:** 2024-07-30
- **Final completion:** 2027-07
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731234, "Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03731234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*